Allergy Therapeutics Share Discussion Threads

[jimmyloser] 03/3/2021 08:17

Trinity Delta also issue their note. Glowing to say the least and raise the value to circa 54p from 51p dyor

[sev22] 03/3/2021 07:48

House Broker finnCap reiterate their 45.0p price target (114% upside).

This excludes the value of US market entry via the Grass MATA MPL vaccine (c.12-17p) or VLP Peanut allergy vaccine (c.5-10p).

[wizzkid211] 03/3/2021 07:08

Allergy Therapeutics achieved sales growth in actual terms of 7% (5% at constant rates(1) ). This growth came mainly from Northern Europe, with Southern Europe being more affected by Covid-19. Pollinex Quattro, Pollinex and Venomil continued to grow well.
Gross profit increased to GBP42.2m (H1 2020: GBP39.1m), which represents a gross margin of 78% (H1 2020: 77%).

[wapper] 03/3/2021 07:05

Great news here this morning. A blue day for sure.

[catch007] 02/3/2021 17:18

jimmyloser: Good find and post TY.

Hoping the results add to the share price momentum

[farmergeorge] 02/3/2021 16:26

Yes, fingers crossed.

[jimmyloser] 02/3/2021 16:13

Video conference being organised by LSE on Allergy tomorrow morning. Positive noises impo

[jimmyloser] 02/3/2021 14:29

by

Lucy Parsons

Allergy Therapeutics has initiated a biomarker study at Imperial College London, which will aim to evaluate its novel virus like particle (VLP) based peanut allergy vaccine candidate.

The study will use human samples and a set of functional and molecular biomarkers to establish the starting dose to be used for its first-in-human phase I study of the VLP-based vaccine candidate.

In addition, this study will work as an early clinical predictor of efficacy of Allergy’s VLP platform, as well as support the investigational new drug application (IND) application for the vaccine.

On top of the biomarker study, a parallel research project with Imperial College has also begun, which is focused on selecting, measuring and analysing pre-clinical and clinical biomarkers for allergen immunotherapy products across Allergy’s portfolio.

“A safe and effective short-course peanut allergy vaccine would be a significant breakthrough product, offering life-changing benefits to sufferers affected by this condition. The data we have generated so far for our peanut vaccine candidate give us confidence in its potential and through this study we have an opportunity to build on that confidence and provide our upcoming Phase I study with the greatest chances of success,” said Manuel Llobet, chief executive officer of Allergy Therapeutics.

“Our collaboration with Imperial College London, who are one of the foremost experts in this field, will equip us with a greater depth of knowledge of allergy biomarkers and their relationship to clinical outcomes, which will be applied to future clinical trials and aid in the development of our allergy immunotherapy pipeline,” he added.

Allergy’s peanut allergy vaccine programme is already supported by a preclinical research package, with pre-clinical proof of concept for sustained immunity and protection against peanut anaphylaxis after one vaccination

[kevraff] 02/3/2021 13:09

Some strong buys today good to see.

[wapper] 02/3/2021 13:00

Looking stronger today. Good news on Peanut front will see this skyrocket. Fingers crossed and good luck LTH's

[jimmyloser] 02/3/2021 12:37

Glass ceiling time for the LTH's

[jimmyloser] 26/2/2021 16:08

Results and News Update? next Wednesday.

[farmergeorge] 18/2/2021 17:57

Thanks for that SEV22.

[farmergeorge] 15/2/2021 22:16

Yes, with 5 times the average volume over the past 2 weeks.

[jpuff] 15/2/2021 20:45

Nice to see it perkier today. GLA

[jimmyloser] 15/2/2021 14:54

Two weeks today most likely
dyor etc

[wapper] 15/2/2021 14:36

This has just got interesting. News on peanut allergy ?

[sev22] 07/2/2021 20:12

Old Shares Investor Presentation but very informative and has convinced me to top up this week.

[jimmyloser] 04/2/2021 09:04

Thanks Sev.
That is interesting but just how long have they held that stake? We know that they spun out of GSK.

My 'Once upon a time' scenario is that once they crack and prove one of the exciting projects that they are working on, then we will be snapped up by a larger vehicle. One with the clout to monetise it.
Time period? Within two years.

And they lived happily ever after?

impo/dyor

[sev22] 04/2/2021 08:22

I was checking Allergy Therapeutics major shareholders on Stockopedia last night and GlaxoSmithKline Plc reported a 1.58% holding (10.1m shares)on the 15th January 2021.

I thought that fact was worth sharing with PIs who visit this bulletin board.

[jimmyloser] 02/2/2021 12:44

Here’s a batch of fresh news and announcements from across Imperial.

From a hunt for common biomarkers of patients with peanut allergies, to a Royal Society professorship for an Imperial solar energy materials expert, here is some quick-read news from across the College.
Peanut allergy ‘vaccine’;

Imperial researchers are on the hunt for biological markers which could ultimately help to treat patients with peanut allergy.

A team, led by Dr Mohamed Shamji at the National Heart & Lung Institute at Imperial, will analyse blood samples from patients with peanut allergy to search for common biomarkers.

The hope is these markers could provide targets for novel therapies to treat the allergy.

Dr Shamji and team will work closely with Allergy Therapeutics, with the data from patients laying the groundwork for future trials of a peanut allergy vaccine, based on an allergen particle from peanuts.

“We’re excited to begin this collaboration,”; said Dr Shamji. “Our work could ultimately lead to a preventative treatment like a traditional vaccination against infectious diseases, rather than typical immunotherapy like desensitisation or drugs.”

[jimmyloser] 01/2/2021 08:56

One has to ask oneself with all these very small trades, if the REDDIT brigade have arrived at AGY?

:-)